Literature DB >> 16611088

Neuropeptides in psychiatric diseases: an overview with a particular focus on depression and anxiety disorders.

C Belzung1, I Yalcin, G Griebel, A Surget, S Leman.   

Abstract

This paper aimed at reviewing the involvement of neuropeptides in various psychiatric diseases, particularly in depression, and anxiety disorders. General features of neuropeptides are first described, including the history of their discovery, their definition, classification, biosynthesis, transport, release, inactivation, as well as their interaction with specific neuronal receptors. The differences with classical neurotransmitters are mentioned, as well as the different patterns of co-transmission. Finally, different mechanisms, both at the cellular and at the systemic level, are proposed that may explain the involvement of these molecules in various psychiatric diseases. Indeed, at the cellular level, a neuropeptide can be involved in a psychiatric disease, either because it is co-localized with a classical neurotransmitter involved in a disease, or because the neuropeptide-containing neuron projects on a target neuron involved in the disease. At the systemic level, a neuropeptide can play a direct role in the expression of a symptom of the disease. This is illustrated by different examples.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16611088     DOI: 10.2174/187152706776359682

Source DB:  PubMed          Journal:  CNS Neurol Disord Drug Targets        ISSN: 1871-5273            Impact factor:   4.388


  17 in total

Review 1.  Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?

Authors:  Guy Griebel; Florian Holsboer
Journal:  Nat Rev Drug Discov       Date:  2012-05-18       Impact factor: 84.694

Review 2.  Role of orexin in the pathophysiology of depression: potential for pharmacological intervention.

Authors:  Mathieu Nollet; Samuel Leman
Journal:  CNS Drugs       Date:  2013-06       Impact factor: 5.749

Review 3.  Pharmacological treatment of anxiety disorders: current treatments and future directions.

Authors:  Frank J Farach; Larry D Pruitt; Janie J Jun; Alissa B Jerud; Lori A Zoellner; Peter P Roy-Byrne
Journal:  J Anxiety Disord       Date:  2012-08-15

4.  Acute Impact of Selected Pyridoindole Derivatives on Fos Expression in Different Structures of the Rat Brain.

Authors:  Romana Koprdova; Jana Osacka; Mojmir Mach; Alexander Kiss
Journal:  Cell Mol Neurobiol       Date:  2017-07-10       Impact factor: 5.046

5.  Increased fear- and stress-related anxiety-like behavior in mice lacking tuberoinfundibular peptide of 39 residues.

Authors:  D B Fegley; A Holmes; T Riordan; C A Faber; J R Weiss; S Ma; S Batkai; P Pacher; A Dobolyi; A Murphy; M W Sleeman; T B Usdin
Journal:  Genes Brain Behav       Date:  2008-09-17       Impact factor: 3.449

6.  Neurotransmission and bipolar disorder: a systematic family-based association study.

Authors:  Jiajun Shi; Judith A Badner; Eiji Hattori; James B Potash; Virginia L Willour; Francis J McMahon; Elliot S Gershon; Chunyu Liu
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2008-10-05       Impact factor: 3.568

Review 7.  50 years of hurdles and hope in anxiolytic drug discovery.

Authors:  Guy Griebel; Andrew Holmes
Journal:  Nat Rev Drug Discov       Date:  2013-09       Impact factor: 84.694

Review 8.  The role of orexin in post-stroke inflammation, cognitive decline, and depression.

Authors:  Juhyun Song; Eosu Kim; Chul-Hoon Kim; Ho-Taek Song; Jong Eun Lee
Journal:  Mol Brain       Date:  2015-03-11       Impact factor: 4.041

Review 9.  Kappa Opioids, Salvinorin A and Major Depressive Disorder.

Authors:  George T Taylor; Francesca Manzella
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

10.  Editorial: Neuropeptides and Behavior: From Motivation to Psychopathology.

Authors:  Deborah Suchecki; Carol F Elias
Journal:  Front Endocrinol (Lausanne)       Date:  2017-08-25       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.